US 12,441,719 B2
Inhibitors of SARM1
Jonathan Bentley, Abingdon (GB); Todd Bosanac, New Milford, CT (US); Andrew Simon Brearley, Chilton (GB); Rajesh Devraj, Chesterfield, MO (US); and Robert Owen Hughes, Newtown, CT (US)
Assigned to Disarm Therapeutics, Inc., Indianapolis, IN (US)
Appl. No. 17/641,653
Filed by Disarm Therapeutics, Inc., Indianapolis, IN (US)
PCT Filed Sep. 11, 2020, PCT No. PCT/US2020/050455
§ 371(c)(1), (2) Date Mar. 9, 2022,
PCT Pub. No. WO2021/050913, PCT Pub. Date Mar. 18, 2021.
Claims priority of provisional application 62/899,444, filed on Sep. 12, 2019.
Prior Publication US 2022/0315568 A1, Oct. 6, 2022
Int. Cl. C07D 413/04 (2006.01); C07D 215/50 (2006.01); C07D 401/04 (2006.01)
CPC C07D 413/04 (2013.01) [C07D 215/50 (2013.01); C07D 401/04 (2013.01)] 10 Claims
 
1. A compound of Formula I-c:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
R2 is selected from the group consisting of hydrogen, halogen, and a substituted or unsubstituted C1-6 aliphatic; and
R3 is selected from the group consisting of hydrogen and halogen, with the proviso that the compound is not:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry